

AMENDMENTS TO THE CLAIMS

- 1.-2. (canceled)
3. (original) A method of preventing breast cancer in a mammal which comprises administering to a mammal in need of such prevention an effective amount of (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol, or a nontoxic pharmacologically acceptable acid addition salt, N-oxide, ester, or quaternary ammonium salt thereof.
4. (canceled)
5. (previously presented) The method of claim 3 wherein (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol or a nontoxic pharmacologically acceptable acid addition salt thereof is administered to the mammal.
6. (previously presented) The method of claim 3 wherein the mammal is a human.
7. (previously presented) The method of claim 6 wherein the human is female.
8. (previously presented) The method of claim 5 wherein the amount of (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol or a nontoxic pharmacologically acceptable acid addition salt thereof is a unit dosage of 0.1 mg to 50 mg administered to the mammal once to four times a day.
9. (previously presented) The method of claim 8 wherein the amount of (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol or a nontoxic pharmacologically acceptable acid addition salt thereof is a unit dosage of 0.25 mg to 25 mg administered to the mammal once to four times a day.
10. (previously presented) The method of claim 9 wherein the (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol or a nontoxic

pharmacologically acceptable acid addition salt thereof is administered to the mammal once a day.

11. (previously presented) The method of claim 10 wherein the mammal is human.

12. (previously presented) The method of claim 11 wherein the human is female.